Circulating exosomes express α(4)β(7) integrin and compete with CD4+ T cells for the binding to Vedolizumab

Vedolizumab (VDZ) is a therapeutic monoclonal antibody approved for the treatment of inflammatory bowel diseases (IBD). VDZ selectively binds to the α4β7 integrin and blocks trafficking of a specific subset of gastrointestinal-homing T-lymphocytes to inflamed tissue. Although VDZ has shown promising...

Descripción completa

Detalles Bibliográficos
Autores principales: Domenis, Rossana, Marino, Marco, Cifù, Adriana, Scardino, Giulia, Curcio, Francesco, Fabris, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661055/
https://www.ncbi.nlm.nih.gov/pubmed/33180848
http://dx.doi.org/10.1371/journal.pone.0242342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661055/
https://www.ncbi.nlm.nih.gov/pubmed/33180848
http://dx.doi.org/10.1371/journal.pone.0242342

Ejemplares similares